Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight the protective roles of ACE inhibitors and ARBs, such as mentioning specific mortality rates—e.g., 'ACEI/ARB group had a death rate of 3.7% compared to 9.8% in non-users.' Posts often reflect a consensus that these medications are potentially beneficial, with phrases like 'we need to consider this evidence' and 'this is a positive development,' demonstrating an optimistic tone about the study's impact and contributing to the strong overall sentiment.
The majority of discussions express strong support for the publication's conclusions regarding the benefits of ACEIs/ARBs.
The topic fascinates many users, evident by the frequency of posts and references to ongoing discussions.
While there are several detailed references to the study, most discussions provide summarized thoughts rather than in-depth analysis.
Users perceive the findings as having significant implications for treatment strategies involving hypertensive patients during COVID-19.
Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansiyon hastalarının bazılarının maalesef korkarak ilaçlarını bıraktıklarını gördük. Mutlaka bu hastalar ve yakınları izlemeli. https://t.co/Vd5M3AWmPt
Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/RMgZRuKdjl
Wow. Pre-Covid19 an article like this is in AJC. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/e9iIE4XI3u
https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patients on ACEi/ARB #coronavirus #COVID19 @AnastasiaSMihai @DrRaniKhatib @SABOURETCardio @GiuseppeGalati_ @BSHeartFailure @BSHNurseForum https://t.co/hhtWZHRoHP
Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. Revisión de https://t.co/3SJvifbqZ3 en https://t.co/nDDP69WGAo #IECAs #ARAs #COVID19 #COVID19SEMERGEN https://t.co/H5e2aEBqpH
ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. https://t.co/wH5VfMte6n #coronavirus @MikeAlbertMD
This video examines the effects of climate change on global biodiversity. It highlights key research findings, the importance of species preservation, and strategies for mitigating ecological impacts. Join us as we…
This video explores the study evaluating the impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on mortality among COVID-19 patients with hypertension. Results…
In this podcast, Neal Tucker examines emerging treatments for Covid-19, including remdesivir and vaccinations. He reviews recent research on the impact of ACE inhibitors and blockers on mortality rates among…
@babfitz Here you have justification for the use of ARBS in severe cases. Besides they have had great candidates to battle with covid, they ve learned a lot from sars cov1 . We are in the second half of 2021 and still no progress. https://t.co/5wqL6z4kud, https://t.co/B69hguelRj,
RT @ASchmaier: ACE/ARB use before & during (!) hospitalization associated with decreased mortality in #COVID19 in retrospective analysis @…
RT @just_me_mac: Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortali…
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/lNUhcu7Ren
Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with #COVID19. https://t.co/nn7U5Uhzg2
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/NAFvkHOeLQ
Congratulations! @CircRes Population Science paper of 2020 goes to Zhang, et al from the June 5th issue showing use of #ACE inhibitors/ARBs is not associated with increased mortality compared to nonusers in #COVID19 patients with hypertension https://t.co/VcHhlMLtMa @LabTouyz https://t.co/EWktaFsn9z
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @EpidemiologyLWW: Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with…
Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19 https://t.co/CP98C94dRF
Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19 #Epidemiology #MedTwitter #MedEd https://t.co/zSE6SBQWfd
RT @EpidemiologyLWW: Re. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with…
Re. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 https://t.co/H33uRElniW
Not sure too many things have moved Covid mortality over 5%. Interesting to see if it works without chronic pre-treatment. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors With Mortality Among Covid Patients | Circulation Research https://t.co/L4VAcDTiwG
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @CircRes: ICYMI: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that us…
RT @headachedoc: If you’re considering which #migraine preventive start for your patient, it might be time for candesartan or lisinopril.…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/3chlZl0PVN
@EricTopol @Bob_Wachter @UCSF @Novartis I'm still cautiously optimistic regarding these ARB and ACEi trials https://t.co/LIXoEYzlHr Targets the relevant viral pathway, and seems to have promising early data : https://t.co/WpBiYCLS3E Fingers are crossed! @Bob_Wachter know of anyone here @UCSF looking for this too? https://t.co/2IxURGZN3D
RT @Shoukmed: I am aware of 4 observational studies that showed no ass btw @ACEIs use and risk of #COVID19 infection/mortality. @NEJM @JAMA…
I am aware of 4 observational studies that showed no ass btw @ACEIs use and risk of #COVID19 infection/mortality. @NEJM @JAMACardio @CircAHA 1. https://t.co/Dd2cx7iGGT 2. https://t.co/73E8VxeeXM 3. https://t.co/MQReHOdWzi 4. https://t.co/WDw0Gj2KPl Do you know any other ones?
@MFrank_44 @RobertLKruse Observational studies so far point in direction of no effect on mortality rates. Examples: https://t.co/LXHZUvGP2q https://t.co/VqPlO0qUHz For a full overview: https://t.co/1CWMI3Udvs
Never jump to conclusions too quickly. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/Xxwl2GiFX7
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. Revisión de https://t.co/3SJvifbqZ3 en https://t.co/nDDP69WGAo #IECAs #ARAs #COVID19 #COVID19SEMERGEN https://t.co/H5e2aEBqpH
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/jC7TCtS4Nu
@faheyc3 Observation data, but a very good start. https://t.co/IYhPvKVO5P https://t.co/lyCl3Qu7Jn
No increased risk of mortality with ARB/ACEI’s in COVID patients #covid https://t.co/1hmgpHnfew
RT @DrLoomba: Association of Inpatient Use of ACE Inhibitors and ARB with Mortality .....COVID-19 | Circulation Research https://t.co/90Cl8…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @ativittta: Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansi…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. Revisión de https://t.co/3SJvifbqZ3 en https://t.co/nDDP69WGAo #IECAs #ARAs #COVID19 #COVID19SEMERGEN https://t.co/b9zsPebXtb
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/ZUfyYxN3W2
The data for inhibiting RAS with ACE1/ARBs look better and better everyday for #COVID19. 58% reduction in mortality in hypertensive hospitalized COVID19 patients with ACEI/ARBs https://t.co/sE8wSgZ6AA
RT @DrRickLanman: Antihypertensive ACE/ARB treatment associated with LOWER COVID-19 mortality in Chinese study. Published in Circulation Re…
ARB/ACEI処方されている人が多いからかも…。 https://t.co/EVdkLLs3vQ https://t.co/6FWfH8MorP
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @probstMD: Two studies looking at ACEi/ARB effect on patients with #COVID19 from Hubei. 1⃣ From @JAMACardio ➡️no association with wors…
No obstante, un estudio retrospectivo realizado en 1128 pacientes con #Covid_19 (de los cuales 188 tomaban los medicamentos), mostró de forma inesperada que los pacientes que toman estos medicamentos presentaban un menor riesgo de muerte (https://t.co/I8Fp2HAPxk). https://t.co/WI0o41k8SJ
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
Antihypertensive ACE/ARB treatment associated with LOWER COVID-19 mortality in Chinese study. Published in Circulation Research. Hypertensives hospitalized with COVID-19 had higher mortality if not on ACE/ARB medication. @natefavini https://t.co/wKOr31VT08 https://t.co/A1e830M77E
RT @probstMD: Two studies looking at ACEi/ARB effect on patients with #COVID19 from Hubei. 1⃣ From @JAMACardio ➡️no association with wors…
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/riCNfOVb0E
Continuando con HAS y el tratamiento con IECA/ARA II en pacientes infectados con COVID-19... Circulation publicó un artículo sobre el tto con IECA/ARA II en pacientes hospitalizados infectados por COVID-19 y su asociación a mortalidad. https://t.co/6vUsS5UtCr
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/ye0H4SfTz3
Again about ACEi/ARB and #COVID19. This study shows that, among hospitalized #Covid_19 patients with hypertension, inpatient use of ACEI/ARB is associated with lower risk of all-cause mortality. https://t.co/WYeog7j5mz
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
RT @SEMERGENap: Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. R…
Los pacientes hipertensos hospitalizados por #COVID19, en tratamiento con #IECAs o #ARAs, parecen tener menos mortalidad. Revisión de https://t.co/3SJvifbqZ3 en https://t.co/nDDP69WGAo #IECAs #ARAs #COVID19 #COVID19SEMERGEN https://t.co/RMh6dNd7dD
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
Two studies looking at ACEi/ARB effect on patients with #COVID19 from Hubei. 1⃣ From @JAMACardio ➡️no association with worse outcomes. https://t.co/YSys1PMzkO 2⃣ From @CircRes ➡️associated with *improved* outcomes. https://t.co/FcxCGeefHN KM-Curve of PSM model: https://t.co/XezOxMm29z
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
Haven't read in detail myself yet. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 https://t.co/C4KuSzqJ4F
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @doctormutlu: Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-ca…
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @doc_Moreno: Veníamos avisando -> Si tu hipertensión esta bien controlada, no cambies la medicación por el COVID y las teorías de IECA/A…
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @toyosh: 臨床的には、みんな気になってる、高血圧患者に対してのACE阻害薬・ARBの使用がCOVIDの転帰を悪化させるのかどうか。 Circulation researchに出た論文の結論は、むしろ死亡率を下げる！！交絡因子とかは考えないといけないけど、少なくとも…
RT @toyosh: 臨床的には、みんな気になってる、高血圧患者に対してのACE阻害薬・ARBの使用がCOVIDの転帰を悪化させるのかどうか。 Circulation researchに出た論文の結論は、むしろ死亡率を下げる！！交絡因子とかは考えないといけないけど、少なくとも…
RT @toyosh: 臨床的には、みんな気になってる、高血圧患者に対してのACE阻害薬・ARBの使用がCOVIDの転帰を悪化させるのかどうか。 Circulation researchに出た論文の結論は、むしろ死亡率を下げる！！交絡因子とかは考えないといけないけど、少なくとも…
RT @toyosh: Clinically, we're all wondering if the use of ACE inhibitors/ARBs in hypertensive patients worsens #COVID19 outcomes. A paper…
Clinically, we're all wondering if the use of ACE inhibitors/ARBs in hypertensive patients worsens #COVID19 outcomes. A paper from Circulation Research concluded that it rather lowers the mortality rate!!! https://t.co/b9768qz9ya
臨床的には、みんな気になってる、高血圧患者に対してのACE阻害薬・ARBの使用がCOVIDの転帰を悪化させるのかどうか。 Circulation researchに出た論文の結論は、むしろ死亡率を下げる！！交絡因子とかは考えないといけないけど、少なくとも死亡率を上げるわけじゃないんだ。 https://t.co/b9768qz9ya
RT @ASchmaier: ACE/ARB use before & during (!) hospitalization associated with decreased mortality in #COVID19 in retrospective analysis @…
RT @RogueRad: ACEI/ARB is associated with lower mortality in COVID. Does this study sufficiently debunk the opposite? https://t.co/UINi6JEG…
RT @BSHeartFailure: At the very least, reassuring data on safety of ACEI/ARB in COVID-infected people. Circ Res 2020 DOI: 10.1161/CIRCRESAH…
An important observation. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/258BApoGme
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
RT @PharmacyPearls: #COVID-19 & The Threat of #Angiotensin Excess https://t.co/PAIbTBLigi via @YouTube #MedEd
#COVID-19 & The Threat of #Angiotensin Excess https://t.co/PAIbTBLigi via @YouTube #MedEd
@gyrfalc63587709 @Rectitude20 I remember when he said that. It was a month ago, maybe more. It was speculation. It needed study. Now they have done some studies, they have shown no link. https://t.co/L7jvomr4ba https://t.co/nYu41S1xcw https://t.co/Bj9g9HPso7
@dris3af @EchoMoonBeam @CNN @andrewcuomo @realDonaldTrump @FoxNews @POTUS @CDCDirector @NIH @RandPaul @tedcruz @SenTedCruz Can you provide any data/studies that found a worse outcome for patients usings ACE Inhibitors? I can post a few recent ones showing the opposite: https://t.co/9IYNPngUui https://t.co/L7jvomr4ba https://t.co/Bj9g9HPso7 https://t.co/6fhbqc8FPc
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/fuLfiAvYiO
@_amit_goyal https://t.co/L7jvomr4ba
ACEI/ARB Treatment Tied To 58% Lower Death Rate In Patients With #Hypertension In Hospitalized Patients With #CoVid19, Analyses Show https://t.co/V6cWo6d10r
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/sUV021zZMY
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @DrRoderickTung: Nice illustration of how initial speculation based on isolated physiological upregulation of ACE2 may actually be the…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @96hage: 高血圧症の新型コロナウイルス感染（COVID-19）患者1128人を調べたところ、ACEI/ARB使用群の死亡率は3.7％、非使用群は9.8％（P = 0.01）。年齢・性別・合併症・服用薬で補正してもACEI/ARB使用群の死亡率は58％低い（ハザード…
高血圧症の新型コロナウイルス感染（COVID-19）患者1128人を調べたところ、ACEI/ARB使用群の死亡率は3.7％、非使用群は9.8％（P = 0.01）。年齢・性別・合併症・服用薬で補正してもACEI/ARB使用群の死亡率は58％低い（ハザード比0.42; P =0.03）。 https://t.co/w70gV4bsf6 https://t.co/n7pbpq1hX1
ACEI/ARB users vs non-users associated with lower adjusted risk of all-cause mortality among hospitalized COVID-19 patients with hypertension https://t.co/lc0ag6V22c #COVID19 #COVID19Rx
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/3xEN3t7sW8
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research
Link(s): ARB and ACE inhibitor study in JAMA Cardiology (Free) https://t.co/8reiv2HqNz ARB and ACE inhibitor study in Circulation Research (Free) https://t.co/kxdgJGJ8o2 CDC news release on cats (Free) https://t.co/MEiAoZzal6 (cont)
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @EMPoisonPharmD: Observational data to refute the conjectural statement in the the lancet letter 3/11 of possible worse outcomes with AC…
Observational data to refute the conjectural statement in the the lancet letter 3/11 of possible worse outcomes with ACE and ARB use in COVID19 Lancet opinion https://t.co/jtWpEKc7ID Refuting Obssrvational study: https://t.co/oplKz6Y01Q #covid19
@IlindelatorreMD Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/K7bGOlJPCS
RT @ativittta: Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansi…
RT @ativittta: Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansi…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
@IngrahamAngle another variable likely overlooked in the #hydroxychloriquine bashing #FakeScience paper cited on #FakeNews : https://t.co/TJsJpmdBgF
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/f6hpDowtVO. Use of ARB/ACEis associated with ⬇️ mortality.
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
RT @ativittta: Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansi…
@EBondarsky @JAMA_current There's also this: https://t.co/UIFvUmUViy
RT @ativittta: Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansi…
Hipertansiyon ilaçlarının bazılarının COVID-19'u kötüleştirdiğine dair hipotezlerle ilgili hazırladığım video yayında. Tansiyon hastalarının bazılarının maalesef korkarak ilaçlarını bıraktıklarını gördük. Mutlaka bu hastalar ve yakınları izlemeli. https://t.co/Vd5M3AWmPt
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
Entre pacientes hospitalizados por COVID-19 con hipertensión, el uso en hospitalización de IECA/BRA se asociaría con un menor riesgo de mortalidad por todas las causas comparados con los que no usan estos medicamentos https://t.co/IY3Cx3MSvm
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research #COVID19 #coronavirus #covidcardiology https://t.co/chqFm6mWje
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/JkbuBpcFeg
Circulation Research https://t.co/ztMfgk3ysI
Wait! Wasn't it just last week that we were being told to STOP ARBs/ACEis?? Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 |
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/zpqBrLDqzo
Long awaited: retrospective multi-center study of 1128 pts in
Important results to at avoid universal discontinuation of this meds in COVID-19 patients: "It is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk." Zhang, P et al. https://t.co/Xj67BvHie6
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/4QFbFxgWQS
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/RMgZRuKdjl
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/1cmhahKtSt
RT @rincondesisifo: (Circulation) Uso de IECA y ARA2 en pac con HTA y #COVID19 hospitalizados y riesgo de mortalidad https://t.co/iRkVpyypE…
RT @tak53381102: 米国循環器病学会の雑誌 中国湖北省、COVID-19診断を受けた成人高血圧患者1128人 ACEI/ARB服用者188人と、服用していない940人で比較 全死因死亡リスクは、ACEI/ARB群の方が低かった（調整後HR、0.42；95％CI、0…
RT @drshafikuchay: A big study: Use of ACE inhibitors and ARB antihypertensive drugs safe in hospitalised Covid-19 patients. https://t.co/…
RT @inaki1954: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/qmIoxWpUsw
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/iL5n7oWLz3
RT @Globalbiosec: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortal…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19, in @CircRes https://t.co/X0oyJrdi8X
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/zzK5ELEfXF
RT @Globalbiosec: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortal…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/LU2hlG8Fhf
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With #COVID-19 | Circulation Confusing title. These pts did better on ARBS/ACEIs. https://t.co/7AwyqkAGkM
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/FYJPq0lJT6
RT @Globalbiosec: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortal…
RT @Globalbiosec: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortal…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With #COVID19 | Circulation Research https://t.co/szjxOdXEjD
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 - PubMed https://t.co/eJW4didT6q
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 https://t.co/KA8JXfkGoc
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/YvWP5szcMW
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research
RT @MartinQuirosMD: Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. L…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/VZnamw0FZQ
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/YGyrQiLSkq
@hamid_safdari @DrWaheedArian @ShoaibAmini2 not much data out there yet, but here is small study https://t.co/IES3ztZofy
RT @MartinQuirosMD: Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. L…
RT @MartinQuirosMD: Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. L…
RT @KaminskiMed: Convincing? Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers…
RT @SABOURETCardio: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mort…
RT @SABOURETCardio: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mort…
RT @MrinalPatnaik: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @MartinQuirosMD: Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. L…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/ewo8zgk1Zl
RT @SABOURETCardio: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mort…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation-the link https://t.co/WM0E7yVPT9
RT @MartinQuirosMD: Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. L…
RT @DanielJDrucker: Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did no…
RT @cpvio: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Amo…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/WnkOa0njBu
RT @DavidLBrownMD: Wow. Pre-Covid19 an article like this is in AJC. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitor…
RT @MartinQuirosMD: Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. L…
RT @Dr_J_Underwood: Interesting data and adjusted analyses for once suggesting chronic use of ACEI /ARB may be associated with lower mortal…
RT @Dr_J_Underwood: Interesting data and adjusted analyses for once suggesting chronic use of ACEI /ARB may be associated with lower mortal…
Análisis retrospectivo de pacientes que tomaban IECA/ARAII (publicado en Circulation). Se asoció con < mortalidad. Los resultados parecen robustos con n= 188vs940. Se mantiene < mortalidad en análisis ajustado y en el propensity score. https://t.co/yxIdcoDRJX
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | https://t.co/bJpiK7nnjl| Glad to see this safety signal| @MPAlexanderMD @mcbunte
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 https://t.co/rij4QZTMJF
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/lggLqmalgf
RT @ASPNeph: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality A…
RT @DavidLBrownMD: Wow. Pre-Covid19 an article like this is in AJC. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitor…
Wow. Pre-Covid19 an article like this is in AJC. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/e9iIE4XI3u
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
RT @ruizjuanc: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality…
New data showing mortality reduction with ACEI/ARB -possible confounding, but .... https://t.co/D4rkQRORfd
RT @cpvio: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Amo…
Adverse association of ACEi /ARA and poor COVID outcomes seems unlikely. https://t.co/HljlDA3ZX6
RT @KaminskiMed: Convincing? Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/WdGx8irQ6K
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With #Hypertension Hospitalized With #COVID-19 | Circulation Research https://t.co/y6HAZ629mM
RT @ASPNeph: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality A…
RT @ruizjuanc: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality…
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/k3jxGGsEk5
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/jw2poYXGDr
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/KQVhn166w2
Convincing? Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Reduced Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/WrmjhnnhU4
@juliocastrom https://t.co/TAOoRAe9hc
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patients on ACEi/ARB #coronavirus #COVID19 @AnastasiaSMihai @DrRaniKhatib @SABOURETCardio @GiuseppeGalati_ @BSHeartFailure @BSHNurseForum https://t.co/hhtWZHRoHP
RT @EnricoCoiera: Apparent protective effect of ACE inhibitors for covid in this observational study https://t.co/EIfoTZwWj4
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/ZJlRjMaVU9 via @nuzzel
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/ay4FXC8825
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research-reduces mortality https://t.co/XsonY0I0HF
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
A retrospective observational data on patients with hypertension & #COVID19 found @CircRes that in-patient treatment with ACEI/ARB was associated with lower all cause mortality. This at least says that using ACEi/ARB is at least not unsafe in #COVID19 https://t.co/R3DncNQI2W
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
Apparent protective effect of ACE inhibitors for covid in this observational study https://t.co/EIfoTZwWj4
RT @DanielJDrucker: Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did no…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
Im just happy angiotensin receptor blockers are showing real promise for saving COVID19 patients! https://t.co/UjnnRAdpmf
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @JorgeLu51688523: @jlvincen https://t.co/otaKi97YGd
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
ACEI do not worsen outcomes in #COVID19 patients . All such claims earlier in the course of #COVID19 pandemic are falling one after the other. Stick to science do not change long proven Management based on claims or case reports !! https://t.co/ARlFW3BgdC
@__philipn__ @VectorSting @RogerAlvarezDO Check it out guys - published yesterday. Finally data suggesting ARB usage might be very protective! https://t.co/Ku8PevGTuZ
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. https://t.co/wH5VfMte6n #coronavirus @MikeAlbertMD
This interesting... and opposite to what I assumed https://t.co/OC7PoZNZX6
RT @DanielJDrucker: Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did no…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https://t.co/ceHzrjzB9s
RT @Abdulellah_M: ACEI/ARB and COVID-19 again, In Circulation AHA, New retrospective multi center study, - 1128 COVID + HTN in chine. - 11…
@jlvincen https://t.co/otaKi97YGd
ACEI/ARB and COVID-19 again, In Circulation AHA, New retrospective multi center study, - 1128 COVID + HTN in chine. - 118 was on ACEI/ARB. - ACEI/ARB compared to other Anti-HTN >> had LOWER mortality. Waiting for more evidence in comparing to non-HTN. https://t.co/BZS6W3mKuB
RT @DanielJDrucker: Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did no…
Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB” https://t.co/SbKwjQvdMG
RT @RobertLKruse: @csentropy Well, the study has been done, and they did see that ACEI/ARB was associated with lower risk of all-cause mort…
RT @RobertLKruse: @csentropy Well, the study has been done, and they did see that ACEI/ARB was associated with lower risk of all-cause mort…
@csentropy Well, the study has been done, and they did see that ACEI/ARB was associated with lower risk of all-cause mortality compared with non-users. More clinical trials are ongoing to investigate this in a prospective manner. https://t.co/p91aoe6NsJ